nVerses Capital’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
Other funds holding KROS
nVerses Capital's KROS Position: Q3 2026 in Review
nVerses Capital sold out of Keros Therapeutics (KROS) in Q3 2026, closing a stake of 13,124 shares — an estimated $140K sold.
nVerses Capital first reported a position in KROS in Q2 2026 and held it in 1 quarter. The position peaked at $140K in Q2 2026. 135 funds tracked by Wall St. Rank hold KROS as of Q3 2026.
- nVerses Capital reported no remaining Keros Therapeutics position as of Q3 2026 after selling out during the quarter.
- nVerses Capital sold 13,124 Keros Therapeutics shares in Q3 2026, an estimated $140K.
- nVerses Capital first reported a position in Keros Therapeutics in Q2 2026 and held it in 1 quarter.
- nVerses Capital's Keros Therapeutics position peaked at $140K in Q2 2026.
- 135 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.
Based on nVerses Capital's 13F filing for Q3 2026.